Application of ihMT MRI in Multiple Sclerosis

Last updated: August 5, 2024
Sponsor: Assistance Publique Hopitaux De Marseille
Overall Status: Active - Recruiting

Phase

N/A

Condition

Multiple Sclerosis

Memory Loss

Neurologic Disorders

Treatment

inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T

inhomogeneous Magnetisation Transfer (ihMT) sequence

Clinical Study ID

NCT03600779
2017-61
  • Ages 18-45
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • For Patients and Controls :

  • Adult patient, male and female, age 18 to 45

  • Patient affiliated with health insurance coverage,

  • Patient who signed a free and informed consent after receiving detailed,understandable and honest information,

  • For patients only :

  • Patient with relapsing-remitting multiple sclerosis according to the McDonald 2010 criteria

  • Disease duration of less than 5 years

  • Patients treated or not treated with first-line disease modifying therapy

  • Detection of at least one post-Gadolinium injection active lesion identified onthe initial brain MRI (T0)

Exclusion

Exclusion Criteria:

  • For patients only :

• Patients with a progressive form of MS other than the early relapsing-remittingform (primary progressive or secondary progressive)

  • For Patients and Controls :

  • Patients with the usual contraindications for MRI (pacemaker, agitation, metalshards, claustrophobia)

  • Patients at risk of non-compliance to the exam: basic problems withunderstanding, confusion, involuntary movements, poor tolerance of prolongedsupine position

  • Patients who are unable to give their consent: problems with understanding,lack of vigilance, confusion

  • Woman who is pregnant and breastfeeding

  • Patients with a history of neurological or psychiatric condition

  • Patients under guardianship or trusteeship

Study Design

Total Participants: 85
Treatment Group(s): 2
Primary Treatment: inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T
Phase:
Study Start date:
June 14, 2018
Estimated Completion Date:
February 13, 2027

Study Description

The development of in vivo biomarkers sensitive to myelin disruption (demyelination and remyelination) represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.

Connect with a study center

  • Assistance Publique Des Hotipaux de Marseille

    Marseille, Paca 13354
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.